CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

China Shineway Pharmaceutical Group Limited

2877

KYG2110P1000

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-24 EDT			5-day change	1st Jan Change
8.96 ^HKD	-0.44%		-5.49%	+23.25%

03-29	China Shineway Pharmaceutical Group Grows 2023 Profit, Declares Interim 2024 Dividend	MT
03-28	China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

China Shineway Pharmaceutical Group Limited Announces First Interim Dividend in Respect of the Fiscal Year 2023, Payable on 17 May 2023

March 30, 2023 at 12:16 am

China Shineway Pharmaceutical Group Limited announced first interim dividend of RMB 0.31 per share for the fiscal year 2023. Record date is 04 May 2023. Payment date is 17 May 2023.

Ex-dividend date is 28 April 2023.

Latest news about China Shineway Pharmaceutical Group Limited

China Shineway Pharmaceutical Group Grows 2023 Profit, Declares Interim 2024 Dividend	03-29	MT
China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
China Shineway Pharmaceutical Group Limited Declares First Interim Dividend in Respect of the Year Ending December 31, 2024, Payable on May 17, 2024	03-28	CI
China Shineway Pharmaceutical to Log Higher Profit in 2023; Shares Up 3%	03-08	MT
China Shineway Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023	03-07	CI
China Shineway Pharmaceutical Logs 22% Rise in Q1-Q3 Turnover	11-03	MT
China Shineway Pharmaceutical Group Limited Announces Resignation of Executive Director	23-10-31	CI
China Shineway Pharmaceutical Group Limited Announces Resignation of Liu Tiejun as Executive Director, Effective 1 November 2023	23-10-31	CI
China Shineway Pharmaceutical’s Profit Rises 48% in H1	23-08-30	MT
China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
China Shineway Pharmaceutical Group Limited Proposes Second Interim Dividend in Respect of the Fiscal Year 2023, Payable on 29 September 2023	23-08-30	CI
China BlueChemical, Unit to Invest in Structured Deposit Products	23-08-03	MT
China Shineway Pharmaceutical’s H1 Profit to Rise By Up to 50%	23-08-03	MT
China Shineway Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023	23-08-03	CI
Bank of China Raises 30 Billion Yuan with Bond Issue	23-06-16	MT
Shineway Pharmaceutical's Q1 Turnover Rises 36%	23-05-08	MT
China Shineway Pharmaceutical Group's 2022 Profit Jumps 29.8%	23-03-30	MT
China Shineway Pharmaceutical Group Limited Announces First Interim Dividend in Respect of the Fiscal Year 2023, Payable on 17 May 2023	23-03-30	CI
China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
China Shineway Pharmaceutical Group Limited Announces Board Changes	23-03-20	CI
Shineway Pharma's Profit to Jump Up to 35% in 2022	23-03-03	MT
China Shineway Pharmaceutical Group Limited Provides Earnings Outlook for the Year Ended 31 December 2022	23-03-03	CI
China Shineway Pharma Sees 22% Boost in Q1-Q3 Turnover	22-11-11	MT
China Shineway Pharmaceutical Group Limited Announces Board Changes	22-10-31	CI
China Shineway Pharmaceutical Group Limited Announces Board and Committee Changes	22-09-30	CI

Chart China Shineway Pharmaceutical Group Limited

Duration

Period

Chart China Shineway Pharmaceutical Group Limited

More charts

China Shineway Pharmaceutical Group Limited is an investment holding company principally engaged in the research and development, manufacture and trading of modern Chinese medicines. Its main products include injections, soft capsules and granules. The Companyâs subsidiaries include Yuan Da International Limited, Hong Zhan International Limited and Shineway Pharmaceutical Sales Company Limited.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for China Shineway Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.306 CNY

Average target price

13.01 CNY

Spread / Average Target

+56.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED	+23.25%	866M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.04%	42.95B
OTSUKA HOLDINGS CO., LTD.	+16.92%	21.38B
SANDOZ GROUP AG	+18.33%	15.05B
CIPLA LIMITED	+19.27%	14.45B
ZYDUS LIFESCIENCES LIMITED	+56.12%	13.04B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.73%	6.72B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+11.21%	5.47B

Generic Pharmaceuticals